anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Enteral nutrition support can be administered by continuous administration or by time-restricted administration in ICU. Continuous feeding is the most popular feeding schedule because of its less nursing burden and reducing the aspiration prevalence theoretically. However, previous studies demonstrated that there was no complications (diarrhea, distension, Ventilator associated pneumonia-VAP incidence, and so on) difference between these two feeding schedule. So in the nutrition guideline (A.S.P.E.N guideline), there was no recommendation about the feeding schedule. However, time-restricted feeding is more physical than continuous feeding. In ICU, the disorder of protein synthesis is a universal problem and is associated with ICU acquired weakness. In some animal researches, time-restricted feeding was proved to have a greater stimulatory effect on protein synthesis than continuous feeding.

Besides of light, time-restricted feeding can adjust the biological rhythms. It is known that biological clocks could affect energy metabolism, emotion and so on. In the "zi wu liu zhu" theory of traditional chinese medicine, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00. So researchers designed the study to compare the time-restricted feeding according to traditional chinese medicine and continuous feeding effect(especially protein synthesis) on ICU patients.
<P>PROBLEM TO BE SOLVED: To provide an emulsion composition superior in safety and stability, and capable of manufacturing easily.  <P>SOLUTION: Soybean oil of 20 g and glycerine of 2.4 g is mixed by agitation using a magnetic stirrer. The mixture is added to a strong alkali ion water to be the total amount of 200 g and primarily emulsified at a condition of a rotation frequency of 12,765 rpm and a period of time of agitation of 30 min in a boiled water bath using an autohomomixer. To the above emulsion, required amounts of the strong alkali ion water and the glycerine are each then added so as to obtain prescribed values of a volume and an osmotic pressure. Furthermore, the above sample is secondarily emulsified at a condition of a pressure of 1,000 bar and pass times of 40 using a high pressure homogenizer to prepare an O/W emulsion (the emulsion composition).  <P>COPYRIGHT: (C)2005,JPO&NCIPI
System for delivery of a biologically active substance into an environment.  The container is comprised of a single member or two mated members and defines first and second compartments. The container includes pores in at least a portion of the container defining the first compartment. The first compartment contains a polymer gel network which undergoes a volume expansion in response to an environmental condition which varies in the biological environment. The second compartment contains an effective amount of a biologically active compound and may include at least one passageway communicating with the biological environment. Drug delivery is initiated and continues only when the appropriate environmental condition or trigger is met, whereupon volume expansion of the polymer gel network causes the biologically active compound to be discharged into the biological environment.
As many as 40% of cancer survivors report experiencing chronic pain, and recent research indicates that pain is not well managed. Opioids are often prescribed during active cancer treatment for pain management, and many cancer survivors continue the same pain management regimen long after completing their cancer treatment. Reports indicate that prescription rates are up to 1.22 times higher for cancer cancer survivors than people without a cancer diagnosis, and the American Society of Clinical Oncology recommends that opioid tapering should be a priority once someone moves into survivorship status. Music interventions have been used for pain management in people with cancer, yet few studies have examined music therapy for chronic pain in cancer survivors. Moreover, none of these studies have not examined opioid use as a measure. Therefore, the overarching goals of this pilot study are to investigate the impact of an interactive music therapy (IMT) intervention on pain management and opioid use in cancer survivors with chronic pain versus a verbal-based support program (social attention control). This pilot study uses a mixed methods intervention design in which qualitative data (i.e. semi-structured follow-up interviews) are embedded within a randomized controlled trial. We will randomize 40 cancer survivors to one of two 10-session treatments: 1) Interactive Music Therapy or 2) Social Attention Control. Primary (mean daily opioid use) and secondary outcomes (pain intensity, pain interference, pain-related self-efficacy, patient perception of change, and physician perception of change in pain management) will be measured at baseline, post-intervention and 3-month follow-up. Follow-up interviews with a subsample of 12 participants and 4 physicians will enable us to gain a better understanding of potential treatment benefits, learn about challenges encountered, and obtain suggestions for treatment optimization. This is the first music therapy study to examine the benefits of music therapy for opioid tapering in cancer survivors with chronic pain and the results will be used to establish estimates of variance for sample size calculations for a larger-scale randomized control trial.
Uniform, stable aq. emulsions of colloidal solns. of oily, fatty or waxy substances or mixts. of such substances are produced using an injector (i.e. water-aspirator pump). The oily, fatty or waxy substance(s), opt. in the molten state, are siphoned by the injector which in turn is fed with water under a pressure of 2-10 (pref. 2-4) atm. (gauge). The emulsification process is carried out continuously, and the emulsion can be recycled to the injector if a finer and/or more stable emulsion is required. Because the mixing chamber in the injector is relatively small, mixing times are short and undesired absorption of water by the disperse phase is minimized. The procedure can be used in the prodn. of emulsions or colloidal solns. of oily, fatty or waxy substances used as textile or leather finishing agents, in foodstuffs, or inpharmaceutical or cosmetic prepns.
BACKGROUND: A growing number of studies have found that antidepressants have anti-inflammatory effects while protecting nerves. Hypidone hydrochloride (YL-0919) is a novel highly selective 5-HT reuptake blocker. Our previous studies have demonstrated that YL-0919 exerts notable antidepressant- and anxiolytic-like as well as procognitive effects. However, whether YL-0919 can be used to treat inflammatory and infectious diseases remain unknown. In this study, we aimed to verify the anti-inflammatory effect of YL-0919 on bacterial meningitis and further explore the potential molecular mechanisms.
METHODS: We performed the experiments on pneumococcal meningitis mice in vivo and S. pneumoniae infected macrophages/microglia in vitro, with or without YL-0919 treatment. Cognitive function was evaluated by open-field task, Morris water maze test, and novel object recognition test. Histopathological staining and immunofluorescence staining were used to detect the pathological damage of meningitis and NLRP3 inflammasome activation in microglia/macrophages. The expression of the STAT1/NLRP3/GSDMD signal pathway was measured by western blots. Proinflammatory cytokines associated with pyroptosis were detected by ELISA.
RESULTS: YL-0919 protected mice from fatal pneumococcal meningitis, characterized by attenuated cytokine storms, decreased bacterial loads, improved neuroethology, and reduced mortality. NLRP3 plays a key role in the regulation of inflammation. When the underlying mechanisms were investigated, we found that YL-0919 inhibited the activation of NLRP3 via STAT1, and thus inhibited macrophages/microglia pyroptosis, resulting in downregulation of proinflammatory cytokines. In addition, Sigma1R was identified as a pivotal receptor that can be engaged by YL-0919 to inhibit NLRP3 activation and pyroptosis pathway in microglia/macrophages.
CONCLUSIONS: These results provide new insights into the mechanisms of inflammation regulation mediated by the antidepressant YL-0919. Moreover, targeting the STAT1/NLRP3 pyroptosis pathway is a promising strategy for the treatment of infectious diseases like bacterial meningitis.
The invention provides an application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia. The total saponins of the bacopa monnieri (L.) wettst. mainly comprise the following dammarane type triterpenoid saponin compounds: bacopaside I, bacoside A3, bacopaside II, bacopasaponin cisomer and bacopasaponin C. The invention further provides an application of the bacopaside I in preparation of a medicament for resisting cerebral ischemia. The experimental study shows that the total saponins of the bacopa monnieri (L.) wettst. and the bacopaside I have the effects of improving the behavioral symptoms caused by cerebral ischemia reperfusion injury, reducing the cerebral infarct volume and reducing the cerebral edema caused by cerebral ischemia of a rat. Therefore, the total saponins of the bacopa monnieri (L.) wettst. can be used for preparing the medicaments for preventing and treating cerebral ischemia. The medicaments for preventing and treating the cerebral ischemia are prepared from the total saponins of the bacopa monnieri (L.) wettst. or bacopaside I as the active component and medicinal accessories by adopting a conventional method. The invention further expands the function of the bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. and provides the novel medicaments for preventing and treating the cerebral ischemia. The bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. have high clinical application values.
The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for detecting and treating prostate cancer. In a specific embodiment, a method for identifying a patient as having aggressive prostate cancer comprising the step of detecting overexpression relative to a control of epithelial cell adhesion molecule (EpCAM), H4 clustered histone 5 (H4C5), and tetratricopeptide repeat domain 3 (TTC3) in a urine sample obtained from the patient. In a more specific embodiment, the detecting step comprises detecting protein or ribonucleic acid (RNA) level of EPCAM, H4C5 and TTC3. In another specific embodiment, the method further comprises detecting overexpression relative to a control of one or more of messenger ribonucleic acid (mRNA), circulating RNA (circRNA), extracellular DNA and long non-coding RNA (lncRNA). The method can further comprise detecting metabolites.
The invention discloses a nano nucleic acid oral liquid for preventing liver cancer. The oral liquid comprises the following components in percentage by weight: 1 to 50% of C32 particle, 0.001 to 10% of guiding object, 0.01 to 25% of nucleic acid inhibitor, 1 to 12% of auxiliary agent, and the balance being water. The diameter of the C32 particle is 160 to 180 nm. The provided oral liquid has a little side and toxic effect and better effect on inhibiting liver cancer. The drug is made into an oral liquid, which is user-friendly, and no surgery is needed. The provided preparation method well preserves the effective chain segments of the guiding object and the nucleic acid inhibitor. The technology is simple and is easy to popularize.
All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
In the scalpel group, the skin incision will be made using the traditional method, with a scalpel (No. 22).
Ischemic damage to the intestinal epithelial barrier, such as in necrotizing enterocolitis or small intestinal volvulus, is associated with higher mortality rates in younger patients. We have recently reported a powerful pig model to investigate these age-dependent outcomes in which mucosal barrier restitution is strikingly absent in neonates but can be rescued by direct application of homogenized mucosa from older, juvenile pigs by a yet-undefined mechanism. Within the mucosa, a postnatally developing network of enteric glial cells (EGCs) is gaining recognition as a key regulator of the mucosal barrier. Therefore, we hypothesized that the developing EGC network may play an important role in coordinating intestinal barrier repair in neonates. Neonatal and juvenile jejunal mucosa recovering from surgically induced intestinal ischemia was visualized by scanning electron microscopy and the transcriptomic phenotypes were assessed by bulk RNA sequencing. EGC network density and glial activity were examined by Gene Set Enrichment Analysis, three-dimensional (3-D) volume imaging, and Western blot and its function in regulating epithelial restitution was assessed ex vivo in Ussing chamber using the glia-specific inhibitor fluoroacetate (FA), and in vitro by coculture assay. Here we refine and elaborate our translational model, confirming a neonatal phenotype characterized by a complete lack of coordinated reparative signaling in the mucosal microenvironment. Furthermore, we report important evidence that the subepithelial EGC network changes significantly over the early postnatal period and demonstrate that the proximity of a specific functional population of EGC to wounded intestinal epithelium contributes to intestinal barrier restitution following ischemic injury.NEW & NOTEWORTHY This study refines a powerful translational pig model, defining an age-dependent relationship between enteric glia and the intestinal epithelium during intestinal ischemic injury and confirming an important role for enteric glial cell (EGC) activity in driving mucosal barrier restitution. This study suggests that targeting the enteric glial network could lead to novel interventions to improve recovery from intestinal injury in neonatal patients.
NEW MATERIAL:The compound of formulaI(X and Y are H or together form a single bond; n is 0-2). EXAMPLE:N-(Diaminophosphinyl)-3-methyl-2-butenamide. USE:Remedy and preventive for urethral lithiasis. It has strong urease inhibiting and antilithic activities, high transferability to the urine, and high safety, and is applicable continually for a long period. It is useful also as a remedy and preventive for nephropyelitis. PROCESS:The compound of formulaIcan be prepared by (1) reacting the carboxylic acid amide of formula II with phosphorus pentachloride to obtain the compound of formula III, (2) reacting the compound with formic acid, and (3) reacting the resultant phosphoric acid chloride of formula IV with ammonia.
Early mortality after hemodialysis (HD) initiation significantly impacts the longevity of HD patients. This study aimed to quantify the effect sizes of risk factors on mortality using various machine learning approaches. A cohort of 3284 HD patients from the CRC-ESRD (2008-2014) was analyzed. Mortality risk models were validated using logistic regression, ridge regression, lasso regression, and decision trees, as well as ensemble methods like bagging and random forest. To better handle missing data and time-series variables, a recurrent neural network (RNN) with an autoencoder was also developed. Additionally, survival models predicting hazard ratios were employed using survival analysis techniques. The analysis included 1750 prevalent and 1534 incident HD patients (mean age 58.4 ± 13.6 years, 59.3% male). Over a median follow-up of 66.2 months, the overall mortality rate was 19.3%. Random forest models achieved an AUC of 0.8321 for first-year mortality prediction, which was further improved by the RNN with autoencoder (AUC 0.8357). The survival bagging model had the highest hazard ratio predictability (C-index 0.7756). A shorter dialysis duration (< 14.9 months) and high modified Charlson comorbidity index scores (7-9) were associated with hazard ratios up to 7.76 (C-index 0.7693). Comorbidities were more influential than age in predicting early mortality. Monitoring dialysis adequacy (KT/V), RAAS inhibitor use, and urine output is crucial for assessing early prognosis.
Paraquat (1,1 '-dimethyl-4,4'-bipyridylium dichloride) is widely used as a herbicide. Accidental or intentional ingestion of paraquat is common in many developing countries such as China, Sri Lanka and Korea because of easy access. The high mortality rate of paraquat is due to its high toxicity and the lack of effective treatments. Thus, the paraquat poisoning becomes one of major medical problem in the developing countries.

Paraquat poisoning is also one of major causes of death among young patients with acute poisoning in China. It is characterized by multiple organ failure and pulmonary fibrosis with respiratory failure. A growing body of evidence suggested that continuous venovenous hemofiltration (CVVH) had a great beneficial role in the treatment of multiple organ dysfunctions. We hypothesized that CVVH might reduce the high mortality rate of paraquat poisoning via restoring the multiorgan function, such as acute hepatic lesion, acute kidney injury, acute lung injury and acute pancreatic injury. We expect to enroll 100 patients from our hospital within 1 week after oral intake of paraquat. All patients were divided into Group 1 and Group 2. Group 1 were treated with a standardized therapeutic regimen including stomach lavage, emergency haemoperfusion and drugs. Group 2 were accepted with standardized treatment plus CVVH. The aim of this prospective clinical study was to evaluate the safety and efficacy of CVVH for the treatment of patients with paraquat poisoning. The survival rate, clinical manifestations and clinical parameters between these two groups were compared.
Buprenorphine, a mu-receptor agonist kappa-receptor antagonist, is 25-50 times as strong as morphine. Buprenorphine is usually used in the treatment of postoperative patients and the patients in cancer terminal phase to relieve pains without worrying about respiratory depression. The present invention relates to a topical formulation, which comprises an antiviral drug, Chinese medicine enhancers, which are pure known structure components and pharmaceutical acceptable vehicles. The Chinese medicine enhancers were obtained from Chinese herbal shown highly significant transdermal enhance effect and/or reserved effect in dermis or epidermis. Those enhancers are oleanolic acid, 18-β-glycyrrhetinic acid, terpineol, β-myrcene, (-)-Α-pinene, Trans-cinnamic acid, ursolic acid and cineole. The average amount of Buprenorphine HCI penetrated after 48 hr is enough for clinical use (15 mg/48 hr/cm<SP>2</SP>) with 10% terpineol.
1. Technical Result Increase in efficiency of treatment of complicated caries of tooth, in particular chronic and acute chronic forms of periodontitis. 2. Essence Filling material comprises diffused in zeolite powder methyluracil, zinc oxide, barium sulfate, eucalyptus oil, eugenol and menthol oil. 3. Field of Application Medicine, in particular stomatology.
Initial Treatment, Maintenance, Safety Extension Periods: RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose. Dosing will be based on participants disease and treatment status at entry to the study.
In March 2020, the World Health Organization secreted COVID-19 as a pandemic. Although most infected individuals can develop effective immunity, the population at risk (elderly, obese and individual with comorbidities) develop a rapid and frequently fatal disease, with severe acute respiratory syndrome, cytokine storm and coagulopathies; for those who recover, severe pulmonary sequels are frequently observed. We propose a phase I clinical trial to test safety and feasibility of NK cells adoptive immunotherapy for COVID-19. Natural Killer cells are innate granular lymphocytes able to rapidly recognize and kill, without previous exposition, altered cells; it is widely recognized as immune effectors specialized in lysing virus infected cells releasing antigens and activating cytokines to antigen presenting cells and, by doing so, stimulating effective adaptive immunity. We hypothesize that the early infusion of highly activated NK cells will activate adaptive immune effectors preventing the severe clinical evolution of COVID-19 infection. Adoptive NK cell immunotherapy for severe virus infections is innovative. Our proposition is in line with the Brazilian Public Health system purposes, which is to offer secure and effective therapies for all COVID-19 infected individuals. Upon proving NK cell immunotherapy effectiveness for serious virus infections, we can evolve to test this strategy for common viruses that cause epidemics and endemics such as the ones caused by Dengue, Zika, Chikungunya, C and B hepatitis and HIV.
Pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
A water-dispersible particle is provided that includes struvite in an amount ranging from 5% to 99.9% by weight of the total dry weight of the particle. A binder component is present in an amount from 1% to 95% by weight. The struvite and the binder component on that contact with water causes particle dispersion into more than 100 pieces. A process for making a water-dispersible particle includes mechanical aggregation of a struvite into a pellet. A binder component is present in the particle in an amount ranging from 1% to 95% by weight. The struvite and the binder component are present in a form such that contact with water causes particle dispersion into more than 100 pieces. The particle is then dried and ready to be applied.
This study will evaluate whether ANEB-001 effectively inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC). All cohorts in part A and B of the study will be randomized, double-blind and placebo-controlled. Randomization is deemed appropriate to avoid selection bias for active compound or placebo treatment. A double-blind and placebo-controlled design is deemed appropriate because of the safety, tolerability and pharmacodynamic assessments that will be performed in this study. By double-blinding the study, bias arising from study subject's or investigator's knowledge about treatment assignment is avoided. Part C does not include a placebo group and will therefore not be blinded.
Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).